NEWS Bruker launches MyGenius PRO
Bruker’s Microbiology and Infection Diagnostics division has launched the MyGenius PRO fully automated, sample- to-answer molecular diagnostics system in Europe. The high-throughput molecular diagnostics system, which is based on PCR (polymerase chain reaction) technology, made its debut at ESCMID Global 2026. Designed for infectious disease
diagnostics, the new sample-to-answer system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operation. Like the medium-throughput BeGenius system, which offers assay and sample matrix flexibility, the new higher-throughput MyGenius PRO automates the entire
New diagnostics brand for Bio-Techne
US life science firm Bio-Techne Corporation has announced a streamlined brand architecture designed to enable scientists and clinicians to more easily find the answers they need based on their application and stage of research including a new diagnostics brand. The company has organised its
products and technologies under three focused portfolio brands – R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics – aligning its solutions with the way modern science progresses from early discovery through translational insights to clinical diagnostics. Bio-Techne has 50 years of history
in scientific discovery and clinical innovation through a diversified portfolio of solutions: from high-quality proteins, antibodies, and small molecules to advanced technologies, including protein analytical instruments and spatial biology platforms, that enable breakthrough research. The Bio-Techne Diagnostics
portfolio provides clinical laboratories and IVD manufacturers with assay kits, IVD-grade reagents, antibodies, molecular controls, calibrators, and proficiency-testing materials needed to design, develop, and validate reliable diagnostic assays. The portfolio supports the full lifecycle of assay development from early design through deployment at scale.
May 2026
WWW.PATHOLOGYINPRACTICE.COM 13
workflow – from patient sample to diagnostic result – enhancing laboratory efficiency and supporting higher- throughput volume testing needs. At launch, the MyGenius PRO IVDR menu will include assays for cytomegalovirus (CMV) and Epstein-Barr
virus (EBV) from whole blood, and BK virus (BKV) from urine, supporting diagnostic testing in immunocompromised patients. Rapid menu expansion, including human immunodeficiency virus type 1 (HIV-1), hepatitis B virus (HBV), hepatitis C virus (HCV), human herpesvirus 6 (HHV-6) IVDR assays, and additional sample matrices, is planned throughout 2026. The MyGenius PRO platform was
developed in a collaboration between ELITechGroup, a Bruker company, and Hitachi High Tech-Corporation, combining complementary expertise in molecular assays, automation and engineering. Hitachi High-Tech will introduce the platform under the tradename LABOSPECT GA-5 in Japan.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
